IMPROV: Improving Prematurity-Related Respiratory Outcomes at Vanderbilt

Sponsor
Vanderbilt University Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT01460576
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
253
2
63
126.5
2

Study Details

Study Description

Brief Summary

The goal of IMPROV is to identify molecular mechanisms that contribute to lung injury and long-term breathing problems in preterm infants by investigating two interrelated biochemical pathways: the urea cycle-nitric oxide pathway and the glutathione pathway. The investigators hypothesize that prematurity-related limitations in the function of these important biochemical pathways contribute to respiratory disease risk over the first year of life.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The primary goal of the IMPROV/PROP study is to identify biomarkers (biochemical, physiological and genetic) and clinical variables that are associated with and thus potentially predictive of pulmonary status in preterm infants at 1 year corrected age. IMPROV will test the hypothesis that biochemical immaturity and functional genetic variation in the urea cycle-nitric oxide (UC-NO) and glutathione (GSH) pathways influence the development and severity of bronchopulmonary dysplasia (BPD), a form of chronic lung disease that affects more than 10,000 premature infants each year in the US. IMPROV will also test the hypothesis that the duration and degree of NO insufficiency and free radical excess predicts BPD severity and correlates with persistence of lung problems after NICU discharge. Our hypothesis implicates (a) an immature liver and gastrointestinal ability to make citrulline and GSH, (b) inadequacy of nutritional amino acid substrate and (c) common genetic variations in the UC-NO and the GSH pathways in the pathogenesis of BPD. These factors limit the ability of the anatomically and functionally immature lung to respond to the physiologic and environmental stress of preterm birth. As part of the PROP multi-center study, novel approaches to characterizing lung status with non-invasive respiratory measures prior to NICU discharge will be employed. A composite primary outcome of morbidity that is based on serial parental reports of respiratory symptoms, medications, hospitalizations and dependence on technology during the first year of life has been developed.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    253 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Improving Prematurity-Related Respiratory Outcomes at Vanderbilt: The Prematurity and Respiratory Outcomes Program (PROP)
    Study Start Date :
    Sep 1, 2011
    Actual Primary Completion Date :
    Dec 1, 2016
    Actual Study Completion Date :
    Dec 1, 2016

    Outcome Measures

    Primary Outcome Measures

    1. Respiratory morbidity [one year corrected age]

      Need for oxygen, respiratory medications, hospital admissions for respiratory disease or a positive response in at least 1 of 4 morbidity domains during at least 2 separate parental interviews.

    Secondary Outcome Measures

    1. bronchopulmonary dysplasia [36 weeks corrected age]

      need for oxygen at 36 weeks based on a room air challenge

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 7 Days
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Infants who are less than or equal to 7 days old;

    • Gestational Age (GA) between 23 weeks and 0/7 days and 28 weeks and 6/7 days

    Exclusion Criteria:
    • The infant is not considered to be viable (decision made not to provide life-saving therapies);

    • Congenital heart disease (not including PDA and hemodynamically insignificant VSD or ASD);

    • Structural abnormalities of the upper airway, lungs or chest wall;

    • Other congenital malformations or syndromes that adversely affect life expectancy or cardio-pulmonary development;

    • Family is unlikely to be available for long-term follow-up.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Jackson Madison County General Hospital Jackson Tennessee United States 38301
    2 Monroe Carell Jr. Children's Hospital at Vanderbilt Nashville Tennessee United States 37232

    Sponsors and Collaborators

    • Vanderbilt University Medical Center
    • National Heart, Lung, and Blood Institute (NHLBI)

    Investigators

    • Principal Investigator: Judy L. Aschner, MD, Albert Einstein College of Medicine; Vanderbilt University School of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Paul Moore, Asscoc. Professor, Vanderbilt University Medical Center
    ClinicalTrials.gov Identifier:
    NCT01460576
    Other Study ID Numbers:
    • 110833
    • 1U01HL101456
    First Posted:
    Oct 27, 2011
    Last Update Posted:
    May 5, 2017
    Last Verified:
    May 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Keywords provided by Paul Moore, Asscoc. Professor, Vanderbilt University Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 5, 2017